The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?